Middle East Pharmaceutical Industries Past Earnings Performance

Past criteria checks 6/6

Middle East Pharmaceutical Industries has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 11.5% per year. Middle East Pharmaceutical Industries's return on equity is 24.7%, and it has net margins of 20.8%.

Key information

2.7%

Earnings growth rate

2.7%

EPS growth rate

Pharmaceuticals Industry Growth	12.4%
Revenue growth rate	11.5%
Return on equity	24.7%
Net Margin	20.8%
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Middle East Pharmaceutical Industries makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SASE:4016 Revenue, expenses and earnings (SAR Millions)
Date	Revenue	Earnings	G+A Expenses
30 Sep 24	387	80	153
30 Jun 24	367	79	141
31 Mar 24	359	76	133
31 Dec 23	338	66	129
30 Sep 23	294	41	120
30 Jun 23	318	59	122
31 Mar 23	291	50	117
31 Dec 22	303	59	114
31 Dec 21	287	66	98
31 Dec 20	302	73	95

Quality Earnings: 4016 has high quality earnings.

Growing Profit Margin: 4016's current net profit margins (20.8%) are higher than last year (14%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4016's earnings have grown by 2.7% per year over the past 5 years.

Accelerating Growth: 4016's earnings growth over the past year (94.7%) exceeds its 5-year average (2.7% per year).

Earnings vs Industry: 4016 earnings growth over the past year (94.7%) exceeded the Pharmaceuticals industry 6.6%.

Return on Equity

High ROE: 4016's Return on Equity (24.7%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/26 14:52
End of Day Share Price	2024/12/26 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Middle East Pharmaceutical Industries Company is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Madhu Appissa	Al Rajhi Capital
null null	SNB Capital